0.00
전일 마감가:
$15.50
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.76B
수익:
$260.81M
순이익/손실:
$20.48M
주가수익비율:
0.00
EPS:
0.13
순현금흐름:
$22.67M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
다이나백스 테크놀로지스 Stock (DVAX) Company Profile
명칭
Dynavax Technologies Corp
전화
(510) 848-5100
주소
2100 POWELL STREET, EMERYVILLE, CA
Compare DVAX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp
|
0.00 | 1.76B | 260.81M | 20.48M | 22.67M | 0.13 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.79 | 58.51B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
117.99 | 49.90B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.995 | 44.64B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.25 | 35.08B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
589.50 | 25.99B | 3.18B | 1.33B | 1.04B | 27.90 |
다이나백스 테크놀로지스 Stock (DVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-02-01 | 개시 | Goldman | Neutral |
| 2022-09-27 | 개시 | JMP Securities | Mkt Outperform |
| 2022-01-06 | 재개 | Goldman | Buy |
| 2021-08-06 | 개시 | Goldman | Buy |
| 2020-08-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-15 | 개시 | Evercore ISI | Outperform |
| 2019-10-18 | 개시 | H.C. Wainwright | Buy |
| 2019-07-11 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-02-27 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-05-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-03-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-09-25 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-07-31 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-05-09 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2016-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-04-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 개시 | RBC Capital Mkts | Outperform |
| 2013-11-25 | 업그레이드 | MLV & Co | Hold → Buy |
| 2013-02-25 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2012-11-16 | 재확인 | MLV & Co | Buy |
모두보기
다이나백스 테크놀로지스 주식(DVAX)의 최신 뉴스
DVAX SEC FilingsDynavax Technolo 10-K, 10-Q, 8-K Forms - Stock Titan
Dynavax Technologies Stock (ISIN: US2681581009) Nears 52-Week High Amid Vaccine Revenue Momentum - AD HOC NEWS
Dynavax Technologies Stock (ISIN: US2681581009) Eyes Steady Gains Amid Biotech Momentum and Revenue - AD HOC NEWS
Growth Report: Does Dynavax Technologies Corporation stock have upside surprise potential2026 Key Lessons & Growth Oriented Trading Recommendations - baoquankhu1.vn
Dynavax Technologies Stock Surges on Vaxart Partnership Validation and Analyst Upside - AD HOC NEWS
Rhenman & Partners Asset Management Boosts Stake in Dynavax Technologies - National Today
Published on: 2026-03-07 01:32:59 - baoquankhu1.vn
USA Herald - USA Herald
DVAX Technical Analysis & ETF Price Forecast - Intellectia AI
[15-12G] DYNAVAX TECHNOLOGIES CORP SEC Filing - Stock Titan
M&A activity drives infectious disease stock rebound - BioWorld MedTech
Can Dynavax Technologies Corporation (DYF1) stock surprise with quarterly resultsJuly 2025 Opening Moves & Safe Capital Investment Plans - mfd.ru
Merger Talk: Does Mangoceuticals Inc have a sustainable dividendJuly 2025 Reactions & Expert Curated Trade Ideas - baoquankhu1.vn
Dynavax Technologies (DVAX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dynavax Technologies Leads Six-Month Stock Returns with 50.05% Gain - Markets Mojo
Sanofi Buyout Ends Dynavax Listing And Shifts Vaccine Upside To Group - Yahoo Finance
A Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value Estimates - Yahoo Finance
Is It Time To Reassess Dynavax (DVAX) After The Agreed Sanofi Cash Acquisition Deal - Yahoo Finance
Sanofi Concludes $2.2 Billion Takeover of Dynavax Technologies - marketscreener.com
Sanofi completes acquisition of Dynavax Technologies, triggers Nasdaq delisting - Investing.com
Dynavax Technologies Announces Board and Officer Changes Following Merger - TradingView
Sanofi closes Dynavax (NASDAQ: DVAX) takeover, delisting shares at $15.50 cash - Stock Titan
Press Release: Sanofi completes the acquisition of Dynavax - Yahoo Finance
Sanofi to merge Dynavax (NASDAQ: DVAX) after $15.50 per share cash tender - Stock Titan
Dynavax Completes Merger and Prepares Nasdaq Delisting - TipRanks
Sanofi Bolsters Vaccine Portfolio with Major Dynavax Acquisition - AD HOC NEWS
Profit Recap: What hedge funds are buying Primech Holdings LtdPortfolio Risk Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Dynavax Technologies Corporation (NASDAQ:DVAX) Receives $24.33 Average Price Target from Analysts - Defense World
Trading Action: Is Dynavax Technologies Corporation forming a bullish divergenceWeekly Profit Report & Low Risk Entry Point Tips - baoquankhu1.vn
DVAX Should I Buy - Intellectia AI
Short Interest in Dynavax Technologies Corporation (NASDAQ:DVAX) Declines By 14.0% - MarketBeat
Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment - simplywall.st
AlphaQuest LLC Boosts Stock Position in Dynavax Technologies Corporation $DVAX - Defense World
Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders - simplywall.st
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - AOL.com
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - The Motley Fool
Sanofi (DVAX) tender offer wins antitrust clearance as shareholders sue - stocktitan.net
Sanofi tender offer progresses; Dynavax (NASDAQ: DVAX) discloses insider holdings and litigation - Stock Titan
Signal Recap: Does Dynavax Technologies Corporation stock have upside surprise potentialJuly 2025 Gainers & AI Driven Stock Movement Reports - baoquankhu1.vn
Dynavax president Novack sells $1.78m in shares - Investing.com
Dynavax CEO ignored last-minute suitor's email after signing $2.2 billion Sanofi deal - The Business Journals
Dynavax Technologies (NASDAQ:DVAX) Stock Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Ocular Therapeutix Rejects Sanofi's Bid, Stock Surges 13% - Intellectia AI
Jim Cramer Highlights Sanofi's Bid for Dynavax - Finviz
Jim Cramer Highlights Sanofi’s Bid for Dynavax - Insider Monkey
Dynavax Technologies Corporation (DVAX) Investor Outlook: Exploring a 30.74% Potential Upside - DirectorsTalk Interviews
Dynavax Shares Surge as Acquisition Battle Looms - AD HOC NEWS
Dynavax (DVAX) Shares Rise 1.9% as New Bidder Emerges Post-Sanofi Deal - Intellectia AI
Dynavax Technologies (NASDAQ:DVAX) Sets New 12-Month HighStill a Buy? - MarketBeat
Dynavax gains on disclosure another bidder interested after deal announced (DVAX:NASDAQ) - Seeking Alpha
Dynavax Technologies stock hits 52-week high at $15.68 - Investing.com
다이나백스 테크놀로지스 (DVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):